Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Blood (2022) 140 (Supplement 1): 947–949.

https://doi.org/10.1182/blood-2022-159412

Published: 2022

Journal Articles

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Blood (2021) 138 (Supplement 1): 463.

https://doi.org/10.1182/blood-2021-145097

Published: 2021

Journal Articles

Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

Blood (2020) 136 (Supplement 1): 11–13.

https://doi.org/10.1182/blood-2020-136539

Published: 2020

Journal Articles

The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial

Christoph Rollig, MD MSC, Hubert Serve, Andreas Hüttmann, MD, Richard Noppeney, MD, Carsten Müller-Tidow, Utz Krug, Claudia D. Baldus, MD, Christian H. Brandts, MD, Volker Kunzmann, MD PhD, Hermann Einsele, Alwin Krämer, MD, Kerstin Schäfer-Eckart, MD, Andreas Neubauer, MD, Andreas Burchert, MD, Aristoteles Giagounidis, MD, Stefan W. Krause, Andreas Mackensen, MD, Walter E. Aulitzky, MD, Regina Herbst, MD, Mathias Hänel, MD, Alexander Kiani, Norbert Frickhofen, MD, Johannes Kullmer, Ulrich Kaiser, MD, Hartmut Link, MD PhD, Thomas Geer, MD, Albrecht Reichle, MD, Christian Junghanss, MD, Roland Repp, MD, Frank Heits, MD, Heinz Albert Durk, Thomas Illmer, Martin Bornhäuser, MD, Markus Schaich, MD, Stefani Barbara Parmentier, MD, Martin Goerner, MD, Christian Thiede, MD, Malte von Bonin, MD, Johannes Schetelig, MD, Michael Kramer, M.Sc., Wolfgang E. Berdel, Gerhard Ehninger

Blood (2017) 130 (Supplement 1): 721.

https://doi.org/10.1182/blood.V130.Suppl_1.721.721

Published: 2017

Journal Articles

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Rüdiger Hehlmann, MD, Michael Lauseker, PhD, Susanne Saussele, MD, Markus Pfirrmann, Stefan W. Krause, MD, Hans-Jochem Kolb, MD, Andreas Neubauer, MD, Dieter K. Hossfeld, Christoph Nerl, MD, Alois Gratwohl, MD, Gabriela M. Baerlocher, Dominik Heim, MD, Tim Henrik Bruemmendorf, Alice Fabarius, PhD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martin C. Müller, MD, Sabine Jeromin, PhD, Ulrike Proetel, PhD, Katharina Kohlbrenner, PhD, Astghik Voskanyan, PhD, Sébastien Rinaldetti, Wolfgang Seifarth, PhD, Birgit Spiess, Leopold Balleisen, MD, Maria E Goebeler, MD, Mathias Hänel, MD, Anthony D. Ho, MD, J Dengler, C Falge, Lothar Kanz, MD, Claus-Henning Köhne, MD, PhD, Andreas Burchert, MD, Michael Kneba, MD PhD, Frank Stegelmann, MD, C Köhne, Hans-Walter Lindemann, C Waller, Michael Pfreundschuh, MD, Karsten Spiekermann, Wolfgang E Berdel, MD, L Müller, Matthias Edinger, MD, Jiri Mayer, Prof, MD SCs, Dietrich W Beelen, MD PhD, Martin Bentz, MD, Hartmut Link, MDPhD, Bernd Hertenstein, MD, R Fuchs, Martin Wernli, MD, F Schlegel, Rudolph Schlag, M de Wit, Lorenz Trümper, MD, H Hebarth, M Hahn, Jörg Thomalla, MD, Christof Scheid, MD, Philippe Schafhausen, MD, Walter Verbeek, MD, Michael J. Eckart, MD, Winfried Gassmann, MD PhD, Antonio Pezzutto, MD, Michael Schenk, Peter Brossart, MD, Thomas Geer, MD, Stephan Bildat, E Schäfer, Andreas Hochhaus, MD, Joerg Hasford

Blood (2017) 130 (Supplement 1): 897.

https://doi.org/10.1182/blood.V130.Suppl_1.897.897

Published: 2017

Journal Articles

Detection of JAK2 Exon 12 Mutations in 10 Patients (10.1%) of V617F Negative PV: A Study of 211 Cases with PV or Suspected PV.

Susanne Schnittger, PhD, Claudia Haferlach, MD, Thomas Geer, MD, Johann Mittermüller, MD, Pedro E. Petrides, MD, Rudolf Schlag, MD, Reiner Sandner, MD, Hans W. Tessen, MD, Jürgen Wehmeyer, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2007) 110 (11): 2541.

https://doi.org/10.1182/blood.V110.11.2541.2541

Published: 2007

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Axel Glasmacher, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Janssens Uwe, MD, Jorg Schubert, MD, Patrick Bruck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, PhD, Susanne Herz, Marie von Lilienfeld-Toal, MD, Ralf Naumann, MD, Marcus Gorschluter, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2007) 110 (11): 4825.

https://doi.org/10.1182/blood.V110.11.4825.4825

Published: 2007

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Ingo G.H. Schmidt-Wolf, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Uwe Janssens, MD, Joerg Schubert, MD, Patrick Brueck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, Ph.D., Susanne Herz, Ph.D., Marie von Lilienfeld-Toal, M.D., Ralph Naumann, MD, Marcus Gorschlueter, MD, Axel Glasmacher, MD

Blood (2006) 108 (11): 3559.

https://doi.org/10.1182/blood.V108.11.3559.3559

Published: 2006

Journal Articles

Safety and Cost Effectiveness of a 10 × 10 9 /L Trigger for Prophylactic Platelet Transfusions Compared With the Traditional 20 × 10 9 /L Trigger: A Prospective Comparative Trial in 105 Patients With Acute Myeloid Leukemia

Hannes Wandt, Markus Frank, Gerhard Ehninger, Christiane Schneider, Norbert Brack, Ali Daoud, Irene Fackler-Schwalbe, Jürgen Fischer, Ringfried Gäckle, Thomas Geer, Peter Harms, Birgit Löffler, Siegfried Öhl, Burkhard Otremba, Monika Raab, Petra Schönrock-Nabulsi, Gerhard Strobel, Rolf Winter, Hartmut Link

Blood (1998) 91 (10): 3601–3606.

https://doi.org/10.1182/blood.V91.10.3601

Published: 1998

NARROW

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Detection of JAK2 Exon 12 Mutations in 10 Patients (10.1%) of V617F Negative PV: A Study of 211 Cases with PV or Suspected PV.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Safety and Cost Effectiveness of a 10 × 10 9 /L Trigger for Prophylactic Platelet Transfusions Compared With the Traditional 20 × 10 9 /L Trigger: A Prospective Comparative Trial in 105 Patients With Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only